Ventrus BioSciences is a pharmaceutical company specializing in the development of late-stage prescription drugs to address gastrointestinal disorders. Among the company’s product candidate portfolio, Iferanserin (VEN 309), one of Ventrus’ lead products and a topical treatment for hemorrhoids, is currently in the midst of phase 3 clinical trials, as is topical diltiazem (VEN 307), which is a treatment for anal fissures. For more information, visit the company’s Web site at www.ventrusbio.com

ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com

Let us hear your thoughts below: